clinical trial · NCT05624554
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Merck Sharp & Dohme LLC·phase3·active not recruiting·n = 300
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaNemtabrutinibFludarabineCyclophosphamideBendamustineRituximabTruximaRuxienceRiabni
brief summary
Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer. Researchers want to know if people who take nemtabrutinib compared to those who take the standard treatments in this study will live longer without their cancer growing, spreading or returning (progression free survival).
started
Mar 16, 2023
primary completion
May 19, 2027
completion
Mar 17, 2031
last updated
Mar 16, 2026
official title
A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol